MERS-CoV vaccine is safe and induces strong immunity in Army-led first-in-human trial

A Middle East respiratory syndrome coronavirus (MERS CoV) vaccine candidate was shown to be safe, well-tolerated, and induced a robust immune response in a Phase 1 first-in-human clinical trial. Initial findings from the trial were published today in The Lancet Infectious Diseases.

source https://www.lifetechnology.com/blogs/life-technology-news-blog/mers-cov-vaccine-is-safe-and-induces-strong-immunity-in-army-led-first-in-human-trial